Skip to content
Sign in
The Markets Desk — Week 44 · Tue 27 Oct 2026
Beats / 13 priced constituents

biopharma

An equal-weight index of the priced names on this beat, rebuilt every Friday from the constituents that were actually in it.

84.5+0.6%base 100 · to 2026-10-23

This week

What happened

Events on biopharma
DateTypeWhat happenedSource
2026-10-26filing6-K: B-share buyback update to 23 Oct 2026Programme started 6 May 2026 has accumulated 25,515,000 B shares for DKK 7,387,348,112; treasury holding 54,314,876 B shares (1.2% of share capital).agent:company-events · SEC EDGAR 6-K
2026-10-26filing8-K: EQ504 first patient dosed; $20.0m milestone private placement closesOn 26 Oct 2026 first patient dosed in the EQ504 single ascending dose trial in Australia; milestone closing issued 14,957,260 shares at $0.57 and 20,130,457 pre-funded warrants at $0.5669; gross proceeds $20.0m.agent:company-events · SEC EDGAR 8-K
2026-10-22filingForm 4 filings: 3 insiders acquire RSUs and deferred stock units3 insiders, 15-20 Oct 2026: Brennan acquired 795 RSUs at $503.47; Sachs 92.694 deferred stock units and Garber 29.272 at $512.44; no sales reported.agent:company-events · SEC EDGAR Form 4
2026-10-20filingForm 4 cluster: 4 Eli Lilly directors acquire deferred stock units at $1,240.34 on 19 Oct 2026Directors Sulzberger (3.9976 units), Luciano (12.8325), Fyrwald (7.9951) and Alvarez (10.0107) acquired stock units deferred in lieu of cash at $1,240.34. No sales.agent:company-events · SEC EDGAR Form 4
2026-10-20filing8-K: Vertex appoints Daniel Brennan to board of directorsBrennan appointed 20 Oct 2026, board size rises from ten to eleven; joins Audit and Finance Committee. $400,000 RSU award vesting Oct 2027. Former Boston Scientific EVP and CFO (Jan 2014 to Jun 2025).agent:company-events · SEC EDGAR 8-K
2026-10-19filing6-K: Share repurchase update, 12-16 Oct 2026Daily purchases 12-16 Oct 2026: 250,000, 245,000, 245,000, 245,000 and 240,000 B shares at DKK 254.86 to 260.67. Accumulated under programme: 24,315,000 shares, DKK 7,075,024,314. Treasury shares 53,114,876.agent:company-events · SEC EDGAR 6-K
2026-10-16contractMaze 8-K: 2,776,007 common shares exchanged for pre-funded warrantsOn 15 Oct 2026 Maze exchanged 2,776,007 common shares held by Frazier Life Sciences funds for pre-funded warrants (exercise price $0.001 per share). Common shares outstanding were 53,931,889 as of 16 Oct 2026.agent:company-events · SEC EDGAR 8-K
2026-10-16filingEli Lilly Schedule 13D: 19.9% stake in TRex BioEvent date 2026-10-13: Lilly holds 5,480,872 common shares, 19.9% of 27,577,535 outstanding, including 875,000 shares bought in the IPO at $14.00 (about $12.3m).agent:company-events · SEC EDGAR SC 13D
2026-10-13filing6-K: Novo Nordisk share repurchases, 5-9 Oct 2026Buybacks 5-9 Oct 2026: 1,245,000 B shares in total; programme total 23,090,000 shares for DKK 6,758,876,433; treasury shares 51,889,876 (1.2%).agent:company-events · SEC EDGAR 6-K
2026-10-06filing6-K: Novo Nordisk share repurchases, 28 Sep-2 Oct 2026Buybacks 28 Sep-2 Oct 2026: 1,225,000 B shares in total; treasury shares 50,644,876 (1.1%).agent:company-events · SEC EDGAR 6-K
2026-10-05filing6-K: Novo Nordisk says FDA extends denecimig BLA reviewFDA review of the denecimig BLA (haemophilia A) is extended with no new timeline; company cites facility remediation, no efficacy or safety deficiencies identified; targets US launch 1H 2027; no impact on 2026 outlook.agent:company-events · SEC EDGAR 6-K
2026-10-05filing8-K Item 8.01: EQ504 Phase 1 trial cleared by HREC and Australian TGAOn 5 Oct 2026 announced HREC approval and TGA CTN clearance for a Phase 1 trial of EQ504; dosing of healthy participants expected to begin by early November 2026.agent:company-events · SEC EDGAR 8-K
2026-10-02filing8-K Item 8.01: first participant dosed in BGE-102 Phase 2 QUELL-DME trialFirst participant dosed in the Phase 2 QUELL-DME trial of oral BGE-102 (NLRP3 inhibitor) in diabetic macular edema; about 180 participants randomized 1:1:1; topline results expected 2H 2027.agent:company-events · SEC EDGAR 8-K
2026-09-29filing8-K Item 5.02: Richard Menziuso appointed VP, Global Controller and PAOBoard appointed Richard Menziuso as VP, Global Controller and Principal Accounting Officer effective 29 Sep 2026; Gregory Weaver remains CFO. Menziuso, 51, was previously VP, Corporate Controller of Centessa Pharmaceuticals.agent:company-events · SEC EDGAR 8-K
2026-09-28filing6-K: Novo Nordisk share repurchases, 21-25 Sep 2026Buybacks 21-25 Sep 2026: 1,215,000 B shares; programme total 20,620,000 shares for DKK 6,139,842,042; treasury shares 49,419,876.agent:company-events · SEC EDGAR 6-K
2026-09-28contract8-K: Viking Therapeutics equity offering and $225m 2.00% convertible notes due 2032On 23 Sep 2026 Viking agreed to sell 7,857,143 shares at $35.00 and $225.0m 2.00% convertible senior notes due 2032; conversion price about $50.75; offerings closed 25 Sep 2026.agent:company-events · SEC EDGAR 8-K

Dated ahead

Dated catalysts ahead
DateCompanyPeriodFirmness
2026-10-28Viking Therapeutics VKTX2026-Q3expected
2026-10-29Eli Lilly LLY2026-Q3confirmed
2026-10-29Amgen AMGN2026-Q3expected
2026-11-02Vertex Pharmaceuticals VRTX2026-Q3expected
2026-11-04Eli Lilly LLY2026-Q3expected
2026-11-04Amgen AMGN2026-Q3expected
2026-11-04Vertex Pharmaceuticals VRTX2026-Q3expected
2026-11-05Denali Therapeutics DNLI2026-Q3expected
2026-11-05BioAge Labs BIOA2026-Q3expected
2026-11-05Neumora Therapeutics NMRA2026-Q3expected
2026-11-06Denali Therapeutics DNLI2026-Q3expected
2026-11-06Unity Biotechnology UBX2026-Q3expected
2026-11-07Structure Therapeutics GPCR2026-Q3expected
2026-11-08Altimmune ALT2026-Q3expected
2026-11-09Unity Biotechnology UBX2026-Q3expected
2026-11-09BioAge Labs BIOA2026-Q3expected
2026-11-09Structure Therapeutics GPCR2026-Q3expected
2026-11-10Maze Therapeutics MAZE2026-Q3expected
2026-11-11Neumora Therapeutics NMRA2026-Q3expected
2026-11-11Equillium, Inc. EQ2026-Q3expected